News
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten with a federal deadline to halt off-brand products.
The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.
4h
Zacks Investment Research on MSNAMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes LingerAmgen’s AMGN stock has declined 10.4% in the past three months. A lot of this price decline is related to the broader ...
As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...
Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.
Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...
Pharmaceutical manufacturing giant Eli Lilly and Co. is exploring potential economic incentives for a $5.9B biomanufacturing ...
Compounding pharmacies are supposed to stop producing the compounded versions of the popular weight loss medications now that ...
1d
Health on MSNThis New Pill Could Rival Ozempic and Wegovy—Will It Make Weight Loss Drugs More Accessible?Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...
The U.S. FDA cleared Novavax Inc.’s COVID-19 vaccine Nuvaxovid for adults 65 and over and people 12-64 years old with at least one underlying condition that puts them at risk of severe outcomes from ...
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results